| Bioactivity | PF-04937319 is a glucokinase activator (GKA) with EC50 value of 154.4 μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus[1].PF-04937319 is designed to maintain glucose-lowering efficacy while mitigating the risk of hypoglycaemia observed with many other GKAs[2]. | ||||||||||||
| Target | EC50: 154.4 μM (GSA) (PF-04937319) | ||||||||||||
| Name | PF-04937319 | ||||||||||||
| CAS | 1245603-92-2 | ||||||||||||
| Formula | C22H20N6O4 | ||||||||||||
| Molar Mass | 432.43 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Dzyurkevich MS, et al. Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus. Sci Rep. 2017 Nov 22;7(1):16072. [2]. Amin NB, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9. |
PF-04937319
CAS: 1245603-92-2 F: C22H20N6O4 W: 432.43
PF-04937319 is a glucokinase activator (GKA) with EC50 value of 154.4 μM, one of the most promising strategies for th
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.